Sugi Predict

Sugi Predict / Targets / CHRNG

CHRNG

Acetylcholine receptor subunit gamma · P07510 · CHRNG on Sugi Atlas →

18,213 patent compounds predicted against CHRNG, 10,359 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Radafaxine Radafaxine (SCHEMBL48964) 1.00 18/20
SCHEMBL1459633 SCHEMBL1459633 1.00 6/20
SCHEMBL1459699 SCHEMBL1459699 0.76 6/20
SCHEMBL240780 SCHEMBL240780 0.58 6/20
Bupropion Bupropion (SCHEMBL38777) 1.00 5/20
Bupropion Bupropion (SCHEMBL60314) 1.00 5/20
Bupropion Bupropion (SCHEMBL300444) 1.00 5/20
SCHEMBL634327 SCHEMBL634327 1.00 5/20
Bupropion Bupropion (SCHEMBL41602) 0.97 5/20
Bupropion Bupropion (SCHEMBL636116) 0.97 5/20
Bupropion Bupropion (SCHEMBL1237221) 0.97 5/20
Bupropion Bupropion (SCHEMBL678781) 0.94 5/20
Bupropion Bupropion (SCHEMBL1237589) 0.86 5/20
Bupropion Bupropion (SCHEMBL1235744) 0.84 5/20
Bupropion Bupropion (SCHEMBL1235748) 0.84 5/20
Bupropion Bupropion (SCHEMBL1238156) 0.84 5/20
Bupropion Bupropion (SCHEMBL1238245) 0.84 5/20
SCHEMBL1226857 SCHEMBL1226857 0.74 5/20
Bupropion Bupropion (SCHEMBL1237438) 0.74 5/20
Bupropion Bupropion (SCHEMBL1238050) 0.74 5/20

Clinical trials — most relevant to CHRNG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia PHASE4COMPLETED
Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block PHASE4COMPLETED
Postoperative Sugammadex After COVID-19 PHASE4UNKNOWN
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) PHASE4COMPLETED
Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD PHASE4COMPLETED
The Early Reversibility of Rocuronium After Different Doses of Neostigmine PHASE4COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders PHASE3NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 PHASE2COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]) PHASE2COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response PHASE2COMPLETED
Nicotinic Receptors and Schizophrenia PHASE1/PHASE2WITHDRAWN
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness PHASE2COMPLETED
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia PHASE2COMPLETED
Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension PHASE2ACTIVE_NOT_RECRUITING
Nicotinic Receptor Genetic Variation and Alcohol Reward PHASE1RECRUITING
Brain Networks and Addiction Susceptibility PHASE1COMPLETED
M1 Schizophrenia PET Study PHASE1COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine nanWITHDRAWN
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease nanCOMPLETED
Cognitive Effects of Mint Essential Oil nanCOMPLETED
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome nanCOMPLETED
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients nanCOMPLETED
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics nanWITHDRAWN
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection nanCOMPLETED
Methacholine, Long-acting M-cholinolytic and beta2-agonist on the Activity of Beta-receptors in Healthy Volunteers nanUNKNOWN
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRNG binder may also engage these)

ProteinNameSimilarity
P18916 — 1.000 P18916 →
P04760 — 1.000 P04760 →
P13536 — 0.996 P13536 →
P25109 — 0.990 P25109 →
P02713 — 0.987 P02713 →
CHRNB1 Acetylcholine receptor subunit beta 0.984 landscape →
P09690 — 0.983 P09690 →
P20782 — 0.983 P20782 →
P04758 — 0.980 P04758 →
P09660 — 0.979 P09660 →
P04759 — 0.977 P04759 →
CHRND Acetylcholine receptor subunit delta 0.975 landscape →
P25110 — 0.974 P25110 →
P02715 — 0.973 P02715 →
CHRNE Acetylcholine receptor subunit epsilon 0.973 landscape →
P02717 — 0.972 P02717 →
P49580 — 0.970 P49580 →
Q9JHJ5 — 0.968 Q9JHJ5 →
P09484 — 0.968 P09484 →
P02716 — 0.967 P02716 →
Q9JJ16 — 0.965 Q9JJ16 →
P05376 — 0.964 P05376 →
CHRNA7 Neuronal acetylcholine receptor subunit alpha-7 0.962 landscape →
HTR3B 5-hydroxytryptamine receptor 3B 0.962 landscape →
P54131 — 0.961 P54131 →
P49579 — 0.960 P49579 →
Q9ERK7 — 0.960 Q9ERK7 →
Q05941 — 0.960 Q05941 →
Q866A2 — 0.960 Q866A2 →
CHRNB2 Neuronal acetylcholine receptor subunit beta-2 0.959 landscape →